Supplementary Material for: Moxibustion for Essential Hypertension and Hypertensive Symptoms: A Systematic Review of 18 Randomized Controlled Trials

Introduction: This systematic review aims to update the evidence for moxibustion for essential hypertension. Methods: Randomized controlled trials (RCTs) comparing moxibustion versus lifestyle intervention or moxibustion plus antihypertensive drugs versus antihypertensive drugs alone were searched in 9 databases up to March 29, 2020. In meta-analyses, mean difference (MD) and proportional odds ratio (pOR) with 95% confidence intervals (CIs) was pooled for continuous and ordinal outcomes, respectively. Results: Eighteen RCTs were included, involving 1,460 patients. Moxibustion decreased systolic (MD –7.85 mm Hg, 95% CI –9.69 to –6.00, p < 0.00001, I² = 46%) and diastolic (MD –4.09 mm Hg, 95% CI –5.45 to –2.73, p < 0.0001, I² = 56%) blood pressures and improved the response to hypotensive treatment (pOR 2.37, 95% CI 1.49–3.75, p = 0.0003, I² = 57%) significantly more than did the control treatment. Moxibustion also significantly relieved headache and dizziness but the effects changed to be statistically nonsignificant after excluding RCTs with a high risk of bias. Moxibustion did not significantly relieve insomnia and anxiety. No adverse events were reported. Conclusions: Based on the current low to moderate quality evidence, our study suggests that moxibustion may have effects on reducing blood pressure. The effects of moxibustion on typical hypertension symptoms and the long-term safety of moxibustion remain uncertain.